Publications by authors named "Deborah Buchner"

Claim this Profile
W
Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer.
Paul J E Miller, Sanjeev Balu, Deborah Buchner, Mark S Walker, Edward J Stepanski

J Med Econ· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.
Swu-Jane Lin, Hind T Hatoum, Deborah Buchner, David Cox, Sanjeev Balu

BMC Health Serv Res· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
Hind T Hatoum, Swu-Jane Lin, Deborah Buchner, David Cox

Support Care Cancer· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Bruce Feinberg, James Gilmore, Sally Haislip, James Jackson, Gagan Jain, Deborah Buchner

Support Care Cancer· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of diurnal and nocturnal gastroesophageal reflux disease symptoms.
Jan-Samuel Wagner, Marco DaCosta DiBonaventura, Sanjeev Balu, Deborah Buchner

Expert Rev Pharmacoecon Outcomes Res· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Chris Craver, Julie Gayle, Sanjeev Balu, Deborah Buchner

J Med Econ· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Lee Schwartzberg, James Jackson, Gagan Jain, Sanjeev Balu, Deborah Buchner

Expert Rev Pharmacoecon Outcomes Res· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
Rodolfo E Bordoni, Bruce A Feinberg, James W Gilmore, Sally Haislip, James H Jackson, Deborah Buchner

Clin Lymphoma Myeloma Leuk· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States.
Chris Craver, Julie Gayle, Sanjeev Balu, Deborah Buchner

J Med Econ· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
Hind T Hatoum, Swu-Jane Lin, Deborah Buchner, Edward Kim

Curr Med Res Opin· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC).
Lee Schwartzberg, Stephen Szabo, James Gilmore, Sally Haislip, James Jackson, Deborah Buchner

Curr Med Res Opin· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Sanjeev Balu, Deborah Buchner, Chris Craver, Julie Gayle

Clin Ther· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of a large-scale population-based asthma management program on pediatric asthma patients and their caregivers.
Archelle Georgiou, Deborah A Buchner, Daniel H Ershoff, Kristin M Blasko, Linda V Goodman

Ann Allergy Asthma Immunol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of respiratory symptoms on health-related quality of life and medical resource utilization of patients treated by allergy specialists and primary care providers.
Lewis J Kanter, Charles J Siegel, Claire F Snyder, Elise M Pelletier, Deborah A Buchner

Ann Allergy Asthma Immunol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and future health care utilization for asthma.
Mark D Eisner, Lynn M Ackerson, Felicia Chi, Amy Kalkbrenner, Deborah Buchner

Ann Allergy Asthma Immunol· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis